AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

Recruitingn/aAges 12 Years - 25 YearsAllNational Institute of Diabetes and Digestive and โ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Background: Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people. Objective: To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people. Eligibility: People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight but not diabetic; (3) or are lean and healthy. Biological parents are also needed. Design: Young participants will visit the NIH clinic once a year for up to 25 years. Each visit will take 4 days. Before each visit, participants will wear devices to track their sleep, activity, and blood sugar levels for 7 to 10 days. At each visit, participants will have tests including: Samples: They will pr

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet the following criteria according to their group: Four categories of participants will be included in this study and the inclusion criteria for each group are given below: 1. Participants with Y-T2DM 1a.Age 12-25 years 1b.Type 2 diabetes mellitus as defined by fasting blood glucose \>= 126 mg/dL OR postprandial blood sugar \>= 200 mg/dL OR Hemoglobin A1c \>= 6.5% per American Diabetes Association Criteria and one element from the medical history consistent with ADA or AAP guidelines including: family history of diabetes and obesity, maternal or personal history of gestational diabetes, high-risk race and ethnicity, history of cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome, physical inactivity, other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans, prediabetes), small or large for gestational age birth weight, history of breastfeeding, gestational history of illicit drugs including alcohol, smoking OR documentation of type 2 diabetes diagnosed at \<=25 years of age with verified medical history (as above). 2\. Youth with overweight/ obesity (Y-OW) 2a. Age 12-25 years 2b. For participants \< 18 years of age, BMI \>= 85th percentile (overweight) and \>= 95th percentile (obesity) for age and sex OR 2c. For participants \>= 18 years of age, BMI \>=25\<30 kg/m\^2 (overweight) or \>=30 kg/m\^2 (obesity) 2d. Participants with obesity may have a diagnosis of prediabetes, defined as fasting blood glucose 100-125 mg/dL OR postprandial blood sugar 140-199 mg/dL OR HbA1c 5.7-6.4 percent (either during testing at NIH or as previously documented on outside medical record). 3\. Healthy control lean participants (Y-Lean) 3a. Age 12-25 years 3b. For participants \< 18 years of age, BMI \<= 85th percentile for age and sex OR 3c. For participants \>=18 years of age, BMI 18-24.99 kg/m\^2. 3d. HbA1c \<5.7 percent (either during testing at NIH or as previously documented on outside medical record). 4\. Biological parents of Y-T2DM, Y-OW and Y-Lean participants 4a. Biological parent of enrolled Y-T2DM, Y-OW and Y-Lean by self-report. EXCLUSION CRITERIA: An individual who meets any of the following criteria for their specific group will be excluded from participation in this study: 1\. Y-T2DM, Y-OW and Y-Lean Participants: 1a. Type 1 diabetes or the presence of \>2 diabetes auto-antibodies (e.g., GAD-65, IA-2 antigen, Zinc transporter 8 autoantibodies). 1. b. Medical, psychiatric or cognitive disorders that will, in the opinion of the investigators, limit the subject s ability to comply with study procedures (specific obesity-related comorbidities are explicitly permitted, including hypertension, hyperlipidemia, obstructive sleep apnea and non-alcoholic steatohepatitis). 1c. Serious medical illnesses or diseases thought to alter metabolism (including moderate to severe renal disease (\< 30 mL/min/1.73m\^2), congenital heart disease, Cushing s syndrome, cancer, or other metabolic diseases associated with diabetes or excess weight). 1d. For participants enrolled at the NIH, dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals. 1e. Unwilling to comply with all study procedures or to adhere to Lifestyle Considerations throughout study duration. 1f. Pregnancy at the time of the screening visit. 1g. Clinically significant anemia OR Hematocrit below the lower limit of normal for age and sex cutoffs. 1. h. For Y-OW Participants- Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 2\. Y-Lean participants: In addition to the above exclusion criteria, any Y-Lean participant who meets any of the following additional criteria will be excluded from the study: 2a. Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators. 2b. Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g., niacin, fish oil, red yeast rice) 2c. History of diabetes or abnormal glucose tolerance 2d.. Abnormal screening labs, including the following: i) ALT or AST \>2 times the upper limit of normal ii) Glycosuria iii) Low eGFR (\<90 mL/min/1.73m\^2)Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data 2e. Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 3\. Biological Parents -No Exclusion Criteria
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

2 sites
Children's National Hospital (CNH)
Washington D.C., United States
National Institutes of Health Clinical Center
Bethesda, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy